Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 1983, the company has established itself as a leader in developing innovative therapies, particularly in the fields of orthopaedics and wound care. Anika's core products, including hyaluronic acid-based treatments, are distinguished by their unique formulation and effectiveness in promoting healing and recovery.
With a strong market position, Anika Therapeutics has achieved significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its reach in major operational regions. The company's commitment to research and development ensures it remains at the forefront of advancements in therapeutic solutions, making it a trusted name in the pharmaceutical industry.
-14 vs industry average
Anika Therapeutics, Inc.’s score of 24 is lower than 38% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Anika Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Anika Therapeutics, Inc.'s reported carbon emissions
Anika Therapeutics, Inc., a pharmaceutical preparation manufacturer headquartered in the US, reported approximately 3.6 million kg CO2e in combined Scope 1 and Scope 2 emissions for the year 2023. This figure includes Scope 1 emissions totalling approximately 1.6 million kg CO2e and Scope 2 emissions amounting to about 2.1 million kg CO2e. For 2022, Anika Therapeutics, Inc. did not disclose specific emissions data. However, their sustainability reporting for 2023 indicates that Scope 3 emissions data, specifically for purchased goods and services, was a missing data point. Anika Therapeutics, Inc. has not established formal reduction targets or commitments with initiatives such as the Science Based Targets initiative (SBTi) or the Climate Pledge. Further details on their broader climate strategy and specific reduction initiatives are not publicly available.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Anika Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Anika Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project